Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Return on Capital Employed for 5 consecutive years, with 0.09% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 24.0% year-over-year to 0.09%, compared with a TTM value of 0.09% through Dec 2025, up 24.0%, and an annual FY2025 reading of 0.1%, up 25.0% over the prior year.
  • Return on Capital Employed was 0.09% for Q4 2025 at Xeris Biopharma Holdings, up from 0.04% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.09% in Q4 2025 and bottomed at 0.83% in Q4 2021.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.19% recorded in 2024.
  • The sharpest move saw Return on Capital Employed surged 50bps in 2022, then increased 1bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.83% in 2021, then skyrocketed by 61bps to 0.33% in 2022, then soared by 42bps to 0.19% in 2023, then increased by 21bps to 0.15% in 2024, then surged by 161bps to 0.09% in 2025.
  • Business Quant data shows Return on Capital Employed for XERS at 0.09% in Q4 2025, 0.04% in Q3 2025, and 0.04% in Q2 2025.